10-K/A: Vaccinex Amends 2023 Annual Report, Cites Audit Signature Omission

Vaccinex, Inc. files an amendment to its 2023 annual report to include the conformed signature of its independent auditor, Deloitte & Touche LLP, which was inadvertently omitted from the original filing.

Summary

• Vaccinex, Inc. has filed an amendment to its 2023 annual report on Form 10-K, solely to include the conformed signature of Deloitte & Touche LLP on the audit report.
• The original filing was made on April 2, 2024, and the signed audit report was received before this date, but the conformed signature was mistakenly left out.
• This amendment does not change any other financial or non-financial information from the original filing and does not reflect any events that occurred after the original filing date.
• The company's financial statements for 2023 and 2022 show a net loss of $20.251 million and $19.815 million, respectively.
• The company's cash and cash equivalents decreased from $6.391 million in 2022 to $1.535 million in 2023.
• The company has a significant accumulated deficit of $339.927 million as of December 31, 2023.
• The company has raised capital through private placements and an open market sale agreement, generating $9.7 million in gross proceeds in 2023.
• The company issued public warrants and pre-funded warrants in October 2023, which are accounted for as liabilities and equity, respectively.
• The company's auditor has raised concerns about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including substantial losses, decreasing cash reserves, and a going concern warning from the auditor. While the company has raised capital, the overall tone is negative due to the financial instability and delisting risk.

Positives

• The company successfully raised $9.7 million through private placements in 2023.
• The company has an open market sale agreement in place to sell additional shares of common stock.
• The company has a research collaboration agreement with Surface Oncology, generating revenue through milestone payments and license fees.

Negatives

• The company experienced a significant net loss of $20.251 million in 2023.
• The company's cash reserves have decreased substantially, raising concerns about its financial stability.
• The company has a large accumulated deficit of $339.927 million.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has received a Nasdaq deficiency notice for not meeting the minimum stockholders' equity requirement.

Risks

• The company faces the risk of delisting from the Nasdaq Capital Market if it fails to meet the minimum stockholders' equity requirement.
• The company's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• The company is dependent on the successful development and commercialization of its product candidates, which is subject to clinical trial uncertainty and regulatory approval.
• The company relies on third-party manufacturers and suppliers, which could lead to supply chain disruptions.
• The company's financial performance is subject to fluctuations and the need to obtain additional funding.

Future Outlook

The company is evaluating different strategies to obtain the required funding of future operations, including public or private sale of equity, debt financing, government funding, collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements with third parties. There is no assurance that the company will be able to secure additional financing.

Management Comments

• Management is currently evaluating different strategies to obtain the required funding of future operations.
• Management has concluded that its plans do not alleviate substantial doubt about the company's ability to continue as a going concern.

Industry Context

The biotechnology industry is characterized by high research and development costs, long development timelines, and regulatory hurdles. Vaccinex, as a clinical-stage company, faces significant financial risks and uncertainties common to other early-stage biotechnology companies.

Comparison to Industry Standards

• Many clinical-stage biotech companies experience significant losses and negative cash flows as they invest heavily in research and development.
• The need for additional funding through various means, such as equity offerings or collaborations, is common in the biotech industry.
• The going concern issue raised by the auditor is not uncommon for companies in this stage of development, especially those with limited revenue streams.
• The company's reliance on third-party manufacturers and suppliers is a standard practice in the industry, but it also introduces supply chain risks.
• The company's reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices.

Corporate Governance

Related Party Transactions

• The company leases its facilities from 1895 Management, Ltd., controlled by an entity affiliated with a director.
• The company has entered into a research collaboration agreement with Surface Oncology, Inc., where a former director was the Chief Business Officer.
• The company has conducted multiple private placements with related parties, including FCMI Parent Co., Vaccinex (Rochester) L.L.C., and entities controlled by directors.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers and partners may be concerned about the company's ability to continue operations and fulfill its obligations.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company needs to regain compliance with Nasdaq listing requirements.
• The company must secure additional funding to continue operations.
• The company will continue to evaluate strategies for funding future operations.
• The company will continue to develop its product candidates.

Key Dates

Keywords

Vaccinex, biotechnology, clinical-stage, financial statements, net loss, cash flow, warrants, private placement, going concern, reverse stock split, Nasdaq, delisting, audit, Deloitte & Touche LLP